



Next Generation Sequencing Panel for Neuromuscular Disorders

Clinical Features:

Neuromuscular disorders (NMD) are a clinically and genetically diverse group of conditions affecting the peripheral nervous system and muscle, including muscular dystrophies, congenital myopathies and congenital myasthenic syndrome [1]. Most NMDs have an underlying genetic basis, although there are also acquired forms NMD such as botulism and pharmaceutical induced myopathies [1]. Onset of symptoms is variable between different NMD, and can range from prenatal onset to childhood or adult onset conditions. It is becoming increasingly recognized that many genes associated with NMD can lead to multiple disease phenotypes in different families, and some can be associated with both autosomal dominant and recessive inheritance [1].

Our Neuromuscular Disorders Sequencing Panel includes sequence analysis of all 113 genes listed below.

Neuromuscular Disorders Sequencing Panel					
ACTA1	CHST14	DYSF	LAMA2	PLEC	SPEG
AGRN	CNTN1	EMD	LAMB2	POMGNT1	STAC3
ALG14	COL12A1	FHL1	LAMP2	POMGNT2	STIM1
ALG2	COL13A1	FKBP14	LARGE	POMK	SYNE1
ANO5	COL6A1	FKRP	LDB3	POMT1	SYNE2
B3GALNT2	COL6A2	FKTN	LIMS2	POMT2	SYT2
B3GNT1	COL6A3	FLNC	LMNA	PREPL	TCAP
BAG3	COLQ	GAA	LMOD3	PTPLA	TMEM43
BIN1	CRYAB	GBE1	LRP4	PYGM	TMEM5
CAPN3	DAG1	GFPT1	MEGF10	RAPSN	TNNT1
CAV3	DES	GMPPB	MTM1	RYR1	TNPO3
CCDC78	DMD	GNE	MUSK	SCN4A	TNXB
CFL2	DNAJB6	HNRNPDL	MYF6	SEPN1	TPM2
CHAT	DNM2	HRAS	MYH2	SGCA	TPM3
CHKB	DOK7	ISPD	MYH7	SGCB	TRAPPC11
CHRNA1	DPAGT1	ITGA7	MYL2	SGCD	TRIM32
CHRNA1	DPM1	KBTBD13	MYOT	SGCG	TTN
CHRNA1	DPM2	KLHL40	NEB	SIL1	VCP
CHRNE	DPM3	KLHL41	ORA1	SNAP25	

Myopathies

Disorder	Description	Typically Associated Genes
Bethlem myopathy	Bethlem myopathy (BM) is a variable autosomal dominant condition, associated with proximal muscle weakness and variable contractures. Onset ranges from the prenatal period to adulthood [2].	COL6A1 [2], COL6A2 [2], COL6A3 [2], COL12A1 [3]
Central core disease	Central core disease is characterized by mild to severe muscle weakness and the finding of characteristic cores on muscle biopsy [4]. Most individuals have a milder form of the condition with mild proximal muscle weakness, however more severe forms of the disease with severe infantile hypotonia and respiratory dysfunction have also been reported [4]. Inheritance is typically autosomal dominant, although cases with autosomal recessive inheritance have also been observed.	RYR1 [5]

Centronuclear myopathy	Centronuclear myopathy (CNM), also known as myotubular myopathy, is a rare muscle disease associated with non-progressive or slowly progressive muscle weakness that can develop from infancy to adulthood [6, 7]. On muscle histopathology, patients with CNM have increased frequency of central nuclei, as well as predominance of type 1 fibers and hypotrophy, in the absence of other significant abnormalities. Approximately 80% of males with a diagnosis of myotubular myopathy by muscle biopsy will have a mutation in <i>MTM1</i> identifiable by sequence analysis, which is an X-linked gene. Dominant and recessive forms of CNM also exist.	BIN1 [8], CCDC78 [9], DNM2 [6], MTM1 [10], MYF6 [11], RYR1 [5], SPEG [12]
Congenital Fiber-Type Disproportion	Congenital fiber-type disproportion (CFTD) is a type of congenital myopathy characterized by hypotonia and muscle weakness that varies from mild to severe [13]. The majority of individuals have static weakness. Other features can include feeding difficulties, respiratory failure, ophthalmoplegia, ptosis, contractures and spinal deformities [13]. Histopathologic findings of the condition include type 1 fibers that are at least 12% smaller than type 2 fibers on muscle biopsy. CFTD can be inherited in an autosomal dominant or recessive manner. X-linked inheritance has also been described in some affected families, however the associated gene has not been identified to date.	ACTA1 [14], LMNA [15], MYH7 [16], RYR1 [17], SEPN1 [18], TPM2 [19], TPM3 [20],
Congenital Myopathy - Other	Congenital myopathies are typically characterized by the presence of specific structural and histochemical features on muscle biopsy and clinical presentation can include congenital hypotonia, muscle weakness, delayed motor milestones, feeding difficulties, and facial muscle involvement [21]. Serum creatine kinase may be normal or elevated. Heterogeneity in presenting symptoms can occur even amongst affected members of the same family.	CNTN1 [22], PTPLA [23], RYR1 [5], TTN [24], HRAS [25], MEGF10 [26], STAC3 [27], MYL2 [28]
Inclusion body myopathy	Inclusion body myopathies are a rare group of disorders with variable clinical presentations, typically including slowly progressive muscle weakness. Findings on muscle biopsy include rimmed vacuoles and collection of cytoplasmic or nuclear 15-21 nm diameter tubulofilaments [29]. Other associated symptoms vary depending on the causative gene, and may also include ophthalmoplegia, Paget's disease of bone, and frontotemporal dementia [29]. Inheritance may be autosomal dominant or recessive.	GNE [29], VCP [29], MYH2 [29]
Danon disease	Danon disease is an X-linked dominant condition affecting primarily cardiac muscle. Intellectual disability and skeletal muscle involvement is variable, with men more severely affected than women. Danon disease is thought to be a form of autophagic vacuolar myopathy, characterized by intracytoplasmic autophagic vacuoles with sarcolemmal features [30]	LAMP2 [31]
Laing distal myopathy	Heterozygous mutations in <i>MYH7</i> have been associated with Laing distal myopathy, which is characterized by weakness in childhood, that initially involves the dorsiflexors of the ankles and great toes, followed by the finger extensors [32].	MYH7 [32]

Marinesco-Sjogren syndrome	Homozygous or compound heterozygous mutations in <i>SIL1</i> are associated with Marinesco-Sjogren syndrome. This condition is characterized by congenital cataracts, myopathy, and delayed psychomotor development. Other features include short stature, hypergonadotropic hypogonadism and skeletal deformities secondary to muscle weakness.	SIL1 [33]
Multiminicore disease	The classic form of multiminicore disease (MmD) is associated with hypotonia, delayed motor development, axial muscle weakness and respiratory dysfunction [34]. Onset is typically in infancy or early childhood. Other subtypes of MmD include a moderate form with hand involvement, a severe prenatal form with arthrogryposis, and an ophthalmoplegic form [34]. MmD is typically inherited in an autosomal recessive manner.	RYR1 [5], SEPN1 [34]
Myofibrillar myopathy	Myofibrillar myopathy is characterized by slowly progressive muscle weakness that can affect both proximal and distal muscles. Other features may include muscle stiffness and aching, peripheral neuropathy, and cardiomyopathy. EMD can be inherited in an autosomal dominant, autosomal recessive or X-linked manner.	BAG3 [35], CRYAB [35], DES [35], DNAJB6 [36], FHL1 [35, 37], FLNC [35], LDB3 [35], MYOT [35]
Myopathy with tubular aggregates	Dominant mutations in <i>STIM1</i> and <i>ORAI1</i> are related to myopathy with tubular aggregates present in fibers on muscle biopsy. These aggregates represent a non-specific finding occurring in a number of different conditions including late-onset forms of familial myopathy.	ORAI1 [38], STIM1 [39]
Nemaline myopathy	Nemaline myopathy is characterized by weakness, hypotonia and depressed or absent deep tendon reflexes. Weakness is typically proximal, diffuse or selective, with or without facial weakness and the diagnostic hallmark is the presence of distinct rod-like inclusions in the sarcoplasm of skeletal muscle fibers [40]. Inheritance may be either autosomal dominant or recessive, and some genes have been observed in association with both inheritance patterns.	ACTA1 [41], CFL2 [42], KBTBD13 [43], NEB [44], LMOD3 [45], TNNT1 [46], TPM2 [19], TPM3 [20], KLHL40 [47], KLHL41 [48]

Muscular Dystrophies

Disorder	Description	Typically Associated Genes
Congenital muscular-dystrophy-dystroglycanopathies	Congenital muscular-dystrophy-dystroglycanopathies are a genetically heterogeneous group of autosomal recessive conditions. Dystroglycanopathies are characterized by a broad congenital muscular dystrophy phenotypic spectrum with and without intellectual disability, eye involvement and brain findings [49].	DAG1 [50], FKTN [51], FKRP [51], ISPD [51], GMPPB [52], LARGE [51], POMK, POMT1 [51], POMT2 [51], POMGNT1 [51], POMGNT2, TMEM5 [53], B3GALNT2 [54], B3GNT1 [55],
Congenital muscular dystrophy - Other	Congenital muscular dystrophies are a genetically and clinically heterogeneous group of disorders typically characterized by weakness and dystrophic pattern on muscle biopsy that is present at birth or during the first months of life. Affected infants typically appear 'floppy' and have low muscle tone and poor spontaneous movements [56]. The clinical course is broadly variable [2]. CMDs can be further classified by the mutated gene, the respective protein's localization and the protein's predicted function [57].	CHKB [58], DPM2 [59], DPM3 [60], ITGA7 [61], LAMA2 [62], LMNA [51], SEPN1 [51], DPM1 [63]

Dystrophinopathies	Dystrophinopathies include a spectrum of muscle diseases associated with the <i>DMD</i> gene, such as Duchenne and Becker muscular dystrophy [64]. The DMD is an X-linked gene, and carrier females can be asymptomatic, or may develop cardiomyopathy.	DMD [64]
Emery Dreifuss muscular dystrophy	Emery Dreifuss muscular dystrophy (EMD) is a skeletal muscle disorder characterized by progressive muscle weakness, contractures and cardiac disease [65]. Onset is typically in early childhood. EMD can be inherited in an autosomal dominant, autosomal recessive or X-linked manner.	EMD [65], LMNA [65], SYNE1 [66], SYNE2 [66], TMEM43 [67]
Limb girdle muscular dystrophy	Limb girdle muscular dystrophy (LGMD) is a term generally used to describe progressive weakness and wasting restricted to the limb musculature (proximal greater than distal), due to a genetic defect that is distinct from X-linked dystrophinopathy [68]. Muscle biopsy can show diffuse variation in fiber size, necrosis, regeneration and fibrosis [68]. Onset of symptoms can range from early childhood to late adulthood, and progression and distribution of the weakness and wasting can vary considerably amongst individuals and subtypes [69]. Inheritance of LGMD can be either autosomal recessive or autosomal dominant.	ANO5 [70], CAPN3 [71], CAV3 [72], DAG1 [73], DES [74], DNAJB6 [75], DYSF [76], FLNC [74], HNRNPDL [77], LIMS2 [74], LMNA [78], MYOT [79], PLEC [80], SGCA [81], SGCB [81], SGCD [81], SGCG [81], TCAP [82], TNPO3 [83], TRAPPC11 [84], TRIM32 [85], TTN [86]
Oculopharyngeal muscular dystrophy	Oculopharyngeal muscular dystrophy (OPMD) is caused by heterozygous mutations in the <i>PABPN1</i> gene. OPMD is characterized by late-onset progressive dysphagia, ptosis of the eyelids, and proximal limb weakness.	PABPN1
Ullrich Congenital Muscular Dystrophy	Ullrich congenital muscular dystrophy (UCMD) is an autosomal recessive condition associated with congenital weakness, hypotonia, joint contractures, and hyperlaxity of distal joints [2].	COL6A1 [2], COL6A2 [2], COL6A3 [2]

Other Neuromuscular Disorders

Disorder	Description	Typically Associated Genes
Congenital myasthenic syndrome	Congenital myasthenic syndromes (CMS) are heterogeneous inherited disorders of neuromuscular transmission characterized by fatigable weakness of the skeletal muscle with onset at or shortly after birth or in early childhood [87]. Severity and progression can vary. Major findings in the neonatal onset subtype include feeding difficulties, poor suck and cry, choking spells, ptosis, facial, bulbar and generalized weakness [87]. Later childhood onset subtypes show abnormal muscle fatigability, delayed motor development, ptosis, and fixed or fluctuating extraocular muscle weakness [87]. Inheritance of CMS can be either autosomal recessive or autosomal dominant.	ALG14 [88], ALG2 [88], AGRN [89], CHAT [87], CHRNA1 [87], CHRNB1 [87], CHRND [87], CHRNE [87], COLQ [90], DOK7 [91], GFPT1 [92], LRP4 [93], MUSK [87], PREPL [94], RAPSN [95], SCN4A [96], DPGAT1 [97], SYT2 [98], COL13A1 [99], LAMB2 [100], SNAP25[101]
Pompe disease	Biallelic mutations in <i>GAA</i> are associated with glycogen storage disease type II (Pompe disease). Classic infantile Pompe disease is characterized by infantile onset hypotonia, muscle weakness, cardiomegaly and hypertrophic cardiomyopathy [102]. Non-classic infantile onset and late-onset forms of the disease also exist, which are also associated with slowly progressive muscle weakness [103].	GAA [104]
McArdle disease	Biallelic mutations in <i>PYGM</i> are associated with McArdle disease, or glycogen storage disease type V. This condition	<i>PYGM</i>

	is characterized by muscle cramping and exercise intolerance with onset in childhood or adolescence, with progressive muscle weakness and atrophy into adulthood. Rhabdomyolysis leading to myoglobinuria can cause renal failure in some patients with McArdle disease. [OMIM#232600]	
Glycogen storage disease IV	Type 4 glycogen storage disease (GSD4) is caused by biallelic mutations in <i>GBE1</i> . GSD4 is characterized by liver disease in childhood which progresses to lethal cirrhosis. The neuromuscular presentation of GSD4 is distinguished by age of onset. These forms include a perinatal lethal type, congenital, childhood with or without cardiomyopathy, and adult with isolated myopathy or adult polyglucosan body disease.	GBE1 [105]
Ehlers-Danlos syndrome	Biallelic mutations in <i>CHST14</i> are associated with a musculocontractural form of EDS which is characterized by craniofacial dysmorphism, congenital contractures of the thumbs and fingers, clubfeet, kyphoscoliosis, hypotonia, hyperextensibility and hypermobility, and ocular involvement. Homozygous or compound heterozygous mutations in <i>FKBP14</i> are associated with Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy and hearing loss.	CHST14 [106]; FKBP14 [107], TNXB [108]

Test methods:

Comprehensive sequence coverage of the coding regions and splice junctions of all genes in this panel is performed. Targets of interests are enriched and prepared for sequencing using the Agilent SureSelect system. Sequencing is performed using Illumina technology and reads are aligned to the reference sequence. Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors. All novel and/or potentially pathogenic variants are confirmed by Sanger sequencing. The technical sensitivity of this test is estimated to be >99% for single nucleotide changes and insertions and deletions of less than 20 bp. **This assay also includes analysis for the recurrent c.930+189C>T deep intronic variant in the *COL6A1* gene.**

Neuromuscular Disorders Sequencing Panel (sequence analysis of 113 genes)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
 Cost: \$2,000
 CPT codes: 81407
 Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Congenital Muscular Dystrophy-Dystroglycanopathy Sequencing Panel (sequence analysis of 14 genes)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
 Cost: \$2,000
 CPT codes: 81407
 Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Nemaline Myopathy Sequencing Panel (sequence analysis of 10 genes)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
 Cost: \$2,000
 CPT codes: 81407
 Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Bethlem Myopathy and Ullrich Muscular Dystrophy Sequencing Panel (sequence analysis of 4 genes)

Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
 Cost: \$2,000
 CPT codes: 81407
 Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Centronuclear Myopathy Sequencing Panel (sequence analysis of 7 genes)

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2,000
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Congenital Myopathy with Fiber-Type Disproportion Sequencing Panel (sequence analysis of 7 genes)

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2,000
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Multiminicore Disease Sequencing Panel (sequence analysis of RYR1 and SEPN1)

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2,000
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Myopathy with Tubular Aggregates Sequencing Panel (sequence analysis of ORAI1 and STIM1)

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2,000
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Emery-Dreifuss Muscular Dystrophy Sequencing Panel (sequence analysis of 6 genes)

Sample specifications: 3 to10 cc of blood in a purple top (EDTA) tube
Cost: \$2,000
CPT codes: 81407
Turn-around time: 8 weeks

Note: We cannot bill insurance for the this panel

Results:

Results, along with an interpretive report, are faxed to the referring physician as soon as they are completed. One report will be issued for the entire Neuromuscular Disorders Sequencing Panel. All abnormal results are reported by telephone.

For more information about our testing options, please visit our website at dnatesting.uchicago.edu or contact us at 773-834-0555.

References:

1. Laing, N.G., *Genetics of neuromuscular disorders*. Crit Rev Clin Lab Sci, 2012. **49**(2): p. 33-48.
2. Reed, U.C., *Congenital muscular dystrophy. Part II: a review of pathogenesis and therapeutic perspectives*. Arq Neuropsiquiatr, 2009. **67**(2A): p. 343-62.
3. Hicks, D., et al., *Mutations in the collagen XII gene define a new form of extracellular matrix-related myopathy*. Hum Mol Genet, 2014. **23**(9): p. 2353-63.
4. Brislin, R.P. and M.C. Theroux, *Core myopathies and malignant hyperthermia susceptibility: a review*. Paediatr Anaesth, 2013. **23**(9): p. 834-41.
5. Jungbluth, H., et al., *Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene*. Neuromuscul Disord, 2007. **17**(4): p. 338-45.
6. Pierson, C.R., et al., *X-linked myotubular and centronuclear myopathies*. J Neuropathol Exp Neurol, 2005. **64**(7): p. 555-64.
7. Fardeau, M. and F. Tome, *Congenital Myopathies*, in *Myology*, A. Engel and C. Franzini-Armstrong, Editors. 1994, McGraw-Hill: New York, NY. p. 1500-1505.
8. Nicot, A.S., et al., *Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy*. Nat Genet, 2007. **39**(9): p. 1134-9.
9. Majczenko, K., et al., *Dominant mutation of CCDC78 in a unique congenital myopathy with prominent internal nuclei and atypical cores*. Am J Hum Genet, 2012. **91**(2): p. 365-71.
10. McEntagart, M., et al., *Genotype-phenotype correlations in X-linked myotubular myopathy*. Neuromuscul Disord, 2002. **12**(10): p. 939-46.
11. Kerst, B., et al., *Heterozygous myogenic factor 6 mutation associated with myopathy and severe course of Becker muscular dystrophy*. Neuromuscul Disord, 2000. **10**(8): p. 572-7.

12. Agrawal, P.B., et al., *SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy*. Am J Hum Genet, 2014. **95**(2): p. 218-26.
13. Clarke, N.F., *Congenital fiber-type disproportion*. Semin Pediatr Neurol, 2011. **18**(4): p. 264-71.
14. Laing, N.G., et al., *Actin mutations are one cause of congenital fibre type disproportion*. Ann Neurol, 2004. **56**(5): p. 689-94.
15. Kajino, S., et al., *Congenital fiber type disproportion myopathy caused by LMNA mutations*. J Neurol Sci, 2014. **340**(1-2): p. 94-8.
16. Muelas, N., et al., *MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy*. Neurology, 2010. **75**(8): p. 732-41.
17. Clarke, N.F., et al., *Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion*. Hum Mutat, 2010. **31**(7): p. E1544-50.
18. Clarke, N.F., et al., *SEPN1: associated with congenital fiber-type disproportion and insulin resistance*. Ann Neurol, 2006. **59**(3): p. 546-52.
19. Donner, K., et al., *Mutations in the beta-tropomyosin (TPM2) gene--a rare cause of nemaline myopathy*. Neuromuscul Disord, 2002. **12**(2): p. 151-8.
20. Ryan, M.M., et al., *Nemaline myopathy: a clinical study of 143 cases*. Ann Neurol, 2001. **50**(3): p. 312-20.
21. Taratuto, A.L., *Congenital myopathies and related disorders*. Curr Opin Neurol, 2002. **15**(5): p. 553-61.
22. Compton, A.G., et al., *Mutations in contactin-1, a neural adhesion and neuromuscular junction protein, cause a familial form of lethal congenital myopathy*. Am J Hum Genet, 2008. **83**(6): p. 714-24.
23. Muhammad, E., et al., *Congenital myopathy is caused by mutation of HACD1*. Hum Mol Genet, 2013. **22**(25): p. 5229-36.
24. Carmignac, V., et al., *C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy*. Ann Neurol, 2007. **61**(4): p. 340-51.
25. Stassou, S., et al., *A new syndrome of myopathy with muscle spindle excess*. J Perinat Med, 2005. **33**(2): p. 179-82.
26. Boyden, S.E., et al., *Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores*. Neurogenetics, 2012. **13**(2): p. 115-24.
27. Stamm, D.S., et al., *Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia*. Am J Med Genet A, 2008. **146A**(14): p. 1832-41.
28. Weterman, M.A., et al., *Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy*. Brain, 2013. **136**(Pt 1): p. 282-93.
29. Broccolini, A. and M. Mirabella, *Hereditary inclusion-body myopathies*. Biochim Biophys Acta, 2015. **1852**(4): p. 644-50.
30. Sugie, K., et al., *Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies*. J Neuropathol Exp Neurol, 2005. **64**(6): p. 513-22.
31. Boucek, D., J. Jirikowic, and M. Taylor, *Natural history of Danon disease*. Genet Med, 2011. **13**(6): p. 563-8.
32. Tajsharghi, H. and A. Oldfors, *Myosinopathies: pathology and mechanisms*. Acta Neuropathol, 2013. **125**(1): p. 3-18.
33. Anttonen, A.K., et al., *The gene disrupted in Marinesco-Sjögren syndrome encodes SIL1, an HSPA5 cochaperone*. Nat Genet, 2005. **37**(12): p. 1309-11.
34. Ferreira, A., et al., *Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multimimicore disease: reassessing the nosology of early-onset myopathies*. Am J Hum Genet, 2002. **71**(4): p. 739-49.
35. Olivé, M., R.A. Kley, and L.G. Goldfarb, *Myofibrillar myopathies: new developments*. Curr Opin Neurol, 2013. **26**(5): p. 527-35.
36. Harms, M.B., et al., *Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy*. Ann Neurol, 2012. **71**(3): p. 407-16.
37. Selcen, D., et al., *Reducing bodies and myofibrillar myopathy features in FHL1 muscular dystrophy*. Neurology, 2011. **77**(22): p. 1951-9.
38. Endo, Y., et al., *Dominant mutations in ORAI1 cause tubular aggregate myopathy with hypocalcemia via constitutive activation of store-operated Ca²⁺ channels*. Hum Mol Genet, 2015. **24**(3): p. 637-48.
39. Müller, H.D., et al., *Dominantly inherited myopathy with novel tubular aggregates containing 1-21 tubulofilamentous structures*. Acta Neuropathol, 2001. **102**(1): p. 27-35.
40. North, K. and M. Ryan, *Nemaline Myopathy*, in GeneReviews [Internet], R. Pagon, T. Bird, and C. Dolan, Editors. 1993, University of Washington: Seattle.
41. Laing, N.G., et al., *Mutations and polymorphisms of the skeletal muscle alpha-actin gene (ACTA1)*. Hum Mutat, 2009. **30**(9): p. 1267-77.
42. Agrawal, P.B., et al., *Nemaline myopathy with minicores caused by mutation of the CFL2 gene encoding the skeletal muscle actin-binding protein, cofilin-2*. Am J Hum Genet, 2007. **80**(1): p. 162-7.
43. Sambuughin, N., et al., *Dominant mutations in KBTBD13, a member of the BTB/Kelch family, cause nemaline myopathy with cores*. Am J Hum Genet, 2010. **87**(6): p. 842-7.
44. Pelin, K., et al., *Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy*. Proc Natl Acad Sci U S A, 1999. **96**(5): p. 2305-10.
45. Yuen, M., et al., *Leiomodin-3 dysfunction results in thin filament disorganization and nemaline myopathy*. J Clin Invest, 2014. **124**(11): p. 4693-708.
46. Johnston, J.J., et al., *A novel nemaline myopathy in the Amish caused by a mutation in troponin T1*. Am J Hum Genet, 2000. **67**(4): p. 814-21.
47. Ravenscroft, G., et al., *Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy*. Am J Hum Genet, 2013. **93**(1): p. 6-18.
48. Gupta, V.A., et al., *Identification of KLHL41 Mutations Implicates BTB-Kelch-Mediated Ubiquitination as an Alternate Pathway to Myofibrillar Disruption in Nemaline Myopathy*. Am J Hum Genet, 2013. **93**(6): p. 1108-17.
49. Mitsuhashi, S. and P.B. Kang, *Update on the genetics of limb girdle muscular dystrophy*. Semin Pediatr Neurol, 2012. **19**(4): p. 211-8.
50. Geis, T., et al., *Homozygous dystroglycan mutation associated with a novel muscle-eye-brain disease-like phenotype with multicystic leucodystrophy*. Neurogenetics, 2013. **14**(3-4): p. 205-13.
51. Sparks, S., et al., *Congenital Muscular Dystrophy Overview*, in GeneReviews [Internet], R. Pagon, et al., Editors. 2012, University of Washington: Seattle.
52. Cars, K.J., et al., *Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of alpha-dystroglycan*. Am J Hum Genet, 2013. **93**(1): p. 29-41.
53. Vuillaumier-Barrot, S., et al., *Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly*. Am J Hum Genet, 2012. **91**(6): p. 1135-43.
54. Stevens, E., et al., *Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of alpha-dystroglycan*. Am J Hum Genet, 2013. **92**(3): p. 354-65.
55. Buysse, K., et al., *Missense mutations in beta-1,3-N-acetylglucosaminyltransferase 1 (B3GNT1) cause Walker-Warburg syndrome*. Hum Mol Genet, 2013. **22**(9): p. 1746-54.
56. Sparks, S., et al., *Congenital Muscular Dystrophy Overview*. 1993.
57. Collins, J. and C.G. Bonnemann, *Congenital muscular dystrophies: toward molecular therapeutic interventions*. Curr Neurol Neurosci Rep, 2010. **10**(2): p. 83-91.
58. Mitsuhashi, S., et al., *A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis*. Am J Hum Genet, 2011. **88**(6): p. 845-51.
59. Barone, R., et al., *DPM2-CDG: a muscular dystrophy-dystroglycanopathy syndrome with severe epilepsy*. Ann Neurol, 2012. **72**(4): p. 550-8.

60. Lefeber, D.J., et al., *Deficiency of Dol-P-Man synthase subunit DPM3 bridges the congenital disorders of glycosylation with the dystroglycanopathies*. Am J Hum Genet, 2009. **85**(1): p. 76-86.
61. Hayashi, Y.K., et al., *Mutations in the integrin alpha7 gene cause congenital myopathy*. Nat Genet, 1998. **19**(1): p. 94-7.
62. Quijano-Roy, S., S. Sparks, and A. Rutkowski, *LAMA2-Related Muscular Dystrophy*, in *GeneReviews [Internet]*, R. Pagon, T. Bird, and C. Dolan, Editors. 2012, University of Washington: Seattle.
63. Yang, A.C., et al., *Congenital disorder of glycosylation due to DPM1 mutations presenting with dystroglycanopathy-type congenital muscular dystrophy*. Mol Genet Metab, 2013. **110**(3): p. 345-51.
64. Le Rumeur, E., *Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies*. Bosn J Basic Med Sci, 2015. **15**(3): p. 14-20.
65. Bonne, G. and S. Quijano-Roy, *Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies*. Handb Clin Neurol, 2013. **113**: p. 1367-76.
66. Puckelwartz, M. and E.M. McNally, *Emery-Dreifuss muscular dystrophy*. Handb Clin Neurol, 2011. **101**: p. 155-66.
67. Liang, W.C., et al., *TMEM43 mutations in Emery-Dreifuss muscular dystrophy-related myopathy*. Ann Neurol, 2011. **69**(6): p. 1005-13.
68. Nigro, V., S. Aurino, and G. Piluso, *Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches*. Curr Opin Neurol, 2011. **24**(5): p. 429-36.
69. Pegoraro, E. and E.P. Hoffman, *Limb-Girdle Muscular Dystrophy Overview*. 1993.
70. Penttilä, S., et al., *Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5*. Neurology, 2012. **78**(12): p. 897-903.
71. Chou, F.L., et al., *Calpain III mutation analysis of a heterogeneous limb-girdle muscular dystrophy population*. Neurology, 1999. **52**(5): p. 1015-20.
72. Fanin, M., et al., *Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes*. Neurology, 2009. **72**(16): p. 1432-5.
73. Hara, Y., et al., *A dystroglycan mutation associated with limb-girdle muscular dystrophy*. N Engl J Med, 2011. **364**(10): p. 939-46.
74. McDonald, K.K., et al., *Exome analysis of two limb-girdle muscular dystrophy families: mutations identified and challenges encountered*. PLoS One, 2012. **7**(11): p. e48864.
75. Sarparanta, J., et al., *Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy*. Nat Genet, 2012. **44**(4): p. 450-5, S1-2.
76. Pegoraro, E. and E. Hoffman, *Limb-Girdle Muscular Dystrophy Overview*, in *GeneReviews [Internet]*, R. Pagon, T. Bird, and C. Dolan, Editors. 1993, University of Washington: Seattle.
77. Vieira, N.M., et al., *A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G)*. Hum Mol Genet, 2014. **23**(15): p. 4103-10.
78. Quijano-Roy, S., et al., *De novo LMNA mutations cause a new form of congenital muscular dystrophy*. Ann Neurol, 2008. **64**(2): p. 177-86.
79. Hauser, M.A., et al., *Myotilin is mutated in limb girdle muscular dystrophy 1A*. Hum Mol Genet, 2000. **9**(14): p. 2141-7.
80. Gundesli, H., et al., *Mutation in exon 1f of PLEC, leading to disruption of plectin isoform 1f, causes autosomal-recessive limb-girdle muscular dystrophy*. Am J Hum Genet, 2010. **87**(6): p. 834-41.
81. Vainzof, M., et al., *Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population*. J Neuro Sci, 1999. **164**(1): p. 44-9.
82. Moreira, E.S., et al., *Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin*. Nat Genet, 2000. **24**(2): p. 163-6.
83. Melià, M.J., et al., *Limb-girdle muscular dystrophy 1F is caused by a microdeletion in the transportin 3 gene*. Brain, 2013. **136**(Pt 5): p. 1508-17.
84. Bögershausen, N., et al., *Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability*. Am J Hum Genet, 2013. **93**(1): p. 181-90.
85. Saccone, V., et al., *Mutations that impair interaction properties of TRIM32 associated with limb-girdle muscular dystrophy 2H*. Hum Mutat, 2008. **29**(2): p. 240-7.
86. Hackman, P., et al., *Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin*. Am J Hum Genet, 2002. **71**(3): p. 492-500.
87. Abicht, A., J. Muller, and H. Lochmuller, *Congenital Myasthenic Syndromes*. 1993.
88. Cossins, J., et al., *Congenital myasthenic syndromes due to mutations in ALG2 and ALG14*. Brain, 2013. **136**(Pt 3): p. 944-56.
89. Huzé, C., et al., *Identification of an agrin mutation that causes congenital myasthenia and affects synapse function*. Am J Hum Genet, 2009. **85**(2): p. 155-67.
90. Chaouch, A., et al., *186th ENMC international workshop: congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands*. Neuromuscul Disord, 2012. **22**(6): p. 566-76.
91. Selcen, D., et al., *Dok-7 myasthenia: phenotypic and molecular genetic studies in 16 patients*. Ann Neurol, 2008. **64**(1): p. 71-87.
92. Senderek, J., et al., *Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect*. Am J Hum Genet, 2011. **88**(2): p. 162-72.
93. Ohkawara, B., et al., *LRP4 third beta-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner*. Hum Mol Genet, 2014. **23**(7): p. 1856-68.
94. Régal, L., et al., *PREPL deficiency with or without cystinuria causes a novel myasthenic syndrome*. Neurology, 2014. **82**(14): p. 1254-60.
95. Gaudon, K., et al., *Multiexon deletions account for 15% of congenital myasthenic syndromes with RAPS mutations after negative DNA sequencing*. J Med Genet, 2010. **47**(12): p. 795-6.
96. Tsujino, A., et al., *Myasthenic syndrome caused by mutation of the SCN4A sodium channel*. Proc Natl Acad Sci U S A, 2003. **100**(12): p. 7377-82.
97. Belaya, K., et al., *Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates*. Am J Hum Genet, 2012. **91**(1): p. 193-201.
98. Herrmann, D.N., et al., *Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic syndrome and nonprogressive motor neuropathy*. Am J Hum Genet, 2014. **95**(3): p. 332-9.
99. Latvanlehto, A., et al., *Muscle-derived collagen XIII regulates maturation of the skeletal neuromuscular junction*. J Neurosci, 2010. **30**(37): p. 12230-41.
100. Maselli, R.A., et al., *Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome*. J Med Genet, 2009. **46**(3): p. 203-8.
101. Shen, X.M., et al., *Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability*. Neurology, 2014. **83**(24): p. 2247-55.
102. van den Hout, H.M., et al., *The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature*. Pediatrics, 2003. **112**(2): p. 332-40.
103. Laforêt, P., et al., *Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation*. Neurology, 2000. **55**(8): p. 1122-8.

104. Leslie, N. and B. Tinkle, *Glycogen Storage Disease Type II (Pompe Disease)*, in *GeneReviews [Internet]*, R. Pagon, T. Bird, and C. Dolan, Editors. 1993, University of Washington: Seattle.
105. Bruno, C., et al., *Neuromuscular forms of glycogen branching enzyme deficiency*. *Acta Myol*, 2007. **26**(1): p. 75-8.
106. Malfait, F., et al., *Musculocontractural Ehlers-Danlos Syndrome (former EDS type VIB) and adducted thumb clubfoot syndrome (ATCS) represent a single clinical entity caused by mutations in the dermatan-4-sulfotransferase 1 encoding CHST14 gene*. *Hum Mutat*, 2010. **31**(11): p. 1233-9.
107. Aldeeri, A.A., et al., *Excessively redundant umbilical skin as a potential early clinical feature of Morquio syndrome and FKBP14-related Ehlers-Danlos syndrome*. *Clin Genet*, 2014. **86**(5): p. 469-72.
108. Pénisson-Besnier, I., et al., *Compound heterozygous mutations of the TNXB gene cause primary myopathy*. *Neuromuscul Disord*, 2013. **23**(8): p. 664-9.

Committed to CUSTOMIZED DIAGNOSTICS, TRANSLATIONAL RESEARCH & YOUR PATIENTS' NEEDS